Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
2007

Heregulin β1 and Resistance in Breast Cancer Cells

Sample size: 77 publication 10 minutes Evidence: moderate

Author Information

Author(s): Iain R Hutcheson, Janice M Knowlden, Steve E Hiscox, Denise Barrow, Julia M W Gee, John F Robertson, Ian O Ellis, Robert I Nicholson

Primary Institution: Cardiff University

Hypothesis

Can heregulin β1 signaling circumvent EGFR blockade in tamoxifen-resistant MCF-7 breast cancer cells?

Conclusion

Heregulin β1 can overcome the inhibitory effects of gefitinib on cell growth and invasion in tamoxifen-resistant cells, suggesting implications for anti-EGFR therapies in breast cancer.

Supporting Evidence

  • HRGβ1 promotes erbB3/erbB2 heterodimerization and AKT pathway activation.
  • Gefitinib inhibits HRGβ1-driven cell growth but not invasion.
  • Combination therapy with gefitinib and PI3K inhibitor LY294002 effectively blocks HRGβ1-mediated signaling.

Takeaway

Heregulin β1 helps cancer cells grow and spread even when a drug tries to stop them, which is important for understanding breast cancer treatment.

Methodology

Tam-R cells were treated with gefitinib and heregulin β1, and effects on cell growth and invasion were assessed through various biochemical assays.

Potential Biases

Potential bias in interpreting results due to the focus on specific signaling pathways.

Limitations

The study primarily focuses on in vitro models, which may not fully replicate in vivo conditions.

Participant Demographics

77 primary breast cancer samples from patients with no prior therapy.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/bcr1754

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication